Ecopipam Reduces Tourette Tic Relapse Risk by 50% with Long-Term Control and No Movement-Related Side Effects
Ecopipam, a novel dopamine D1 receptor antagonist, has demonstrated a significant reduction in relapse risk for pediatric and overall populations with Tourette syndrome, cutting recurrence by approximately 50% with durable ... Read More